Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
NRG Oncology
University of Chicago
National Cancer Institute (NCI)
OncoC4, Inc.
Eastern Cooperative Oncology Group
Samsung Medical Center
Ohio State University Comprehensive Cancer Center
Dana-Farber Cancer Institute
SWOG Cancer Research Network
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
University of Arizona
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
SWOG Cancer Research Network
University College, London
Case Comprehensive Cancer Center